Benjamin Alba Email & Phone Number

Thousand Oaks, Ca, Us

Thousand Oaks, Ca, Us

Thousand Oaks, Ca, Us

- Lead of mammalian expression group (May 2018 - present) with expertise in transient and stable pool expression to produce recombinant proteins; experience with various protein classes (mAb, bispecific mAb, immunogens, target proteins for HTS or lot release assays, challenging proteins with low titers and/or clipping); leverage CHO and HEK 293 hosts- Team member for BiTE programs, other IO programs; partner with colleagues in PKDM, bioanalytics, biomarkers, etc. to manage key reagents which support drug release assays, PK assays, etc. for clinical programs (on-going)- Manage outsourcing of recombinant protein production, working with team at Syngene Amgen Research and Development Center (SARC) (late 2017 - present)- Owner of fee-for-service budget for other reagent protein outsourcing (2017 - present)

Thousand Oaks, Ca, Us

Protein Technologies works with Therapeutic Areas to support drug discovery programs- BiTE technology (over the years, functional lead for >15 early discovery programs)- Membrane protein targets for HT screening and immunizations; technologies and strategies to increase success with such targets; Manager of Ph.D. scientist and staff in the discipline of membrane protein expression/ purification (2015-2019)- Contributor to development of novel LIMS system for Biologics; led cross-functional team to implement business rules for the standardization of large molecule nomenclature and sequence feature annotations for research molecules; standardize other sequence components, such as tags, antibody parts, etc.- High-throughput cloning technologies; Microbial expression (E. coli and Pichia pastoris)- 2016-2018: Supervisor of Univ. San Francisco graduate school students during theirinternships at Amgen; community outreach to local college students

Thousand Oaks, Ca, Us

I was a member of the 'Selection and Platform Engineering Group' within Biologics Discovery.Focus areas:- Phage and yeast display- Modalities: alternative protein scaffolds, antibodies, BiTEs, other biologics; albumin engineering- Team member on diverse discovery/pre-clinical programs- Construction of multi-specific biotherapeutics- Leader of technology team developing serum half-life extension methods for biologics- Immunization strategies with nanoparticles or VLPs- Biologics lead for BiTE programs

Thousand Oaks, Ca, Us

Avidia was acquired by Amgen, and the Avidia group continued working on many Avimer programs while in the Amgen Protein Sciences Dept. Programs included inflammation and oncology projects, as well as serum half-life extension and other technology development projects (multi-specific biologics; tissue-targeting modalities, etc.).

Stuart , Us

I worked on various novel Avimer (a small protein scaffold) drug discovery programs; phage- or phagemid-displayed Avimer libraries; high-throughput screening of target-binding Avimers from phage pannings; Avimer affinity-maturation phage libraries and pannings

Ph.D., Biochemistry And Molecular Biology

B.S., Microbiology